PSORIATIC ERYTHRODERMA

Clinical trials for PSORIATIC ERYTHRODERMA explained in plain language.

Never miss a new study

Get alerted when new PSORIATIC ERYTHRODERMA trials appear

Sign up with your email to follow new studies for PSORIATIC ERYTHRODERMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Doubling the dose: a new hope for psoriasis patients losing treatment benefits

Disease control Completed

This study tested whether doubling the dose of the drug TA-650 could help patients with moderate-to-severe psoriasis who initially responded to a standard dose but later saw their symptoms return. The trial involved 51 adults with different forms of psoriasis, including plaque ps…

Matched conditions: PSORIATIC ERYTHRODERMA

Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control

Last updated Mar 18, 2026 14:40 UTC

PSORIATIC ERYTHRODERMA

Get alerted when new PSORIATIC ERYTHRODERMA trials appear

Doubling the dose: a new hope for psoriasis patients losing treatment benefits